SCHEMBL5542363

SCHEMBL5542363

O=CN(Cc1ccccc1)Cc1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.48
GAA P10253 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
PNMT P11086 1/20 0.44
NR3C1 P04150 1/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
PYCR1 P32322 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
RIPK1 Q13546 1/20 0.42
TAAR1 Q96RJ0 2/20 0.42
BCHE P06276 1/20 0.42
CTBP2 P56545 1/20 0.41
G6PC1 P35575 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548405 0.84 G6PC1 (0.49) TAS2R14SIGMAR1NR3C1G6PC1KDM4E
SCHEMBL26802 0.83 ALDH1A1 (0.48) TSHRG6PC1KDM4E
SCHEMBL5543736 0.79 MEN1 (0.50) TAS2R14NR3C1RIPK1TAAR1
SCHEMBL5539533 0.79 PTGES (0.50) SIGMAR1NR3C1PYCR1RIPK1TAAR1
SCHEMBL5547339 0.77 PYCR1 (0.53) GAAPNMTTSHRRECQLPYCR1
SCHEMBL6233069 0.77 PNMT (0.50) PNMTTSHRRECQLPYCR1CHRM2
SCHEMBL2093397 0.77 PGR (0.41) TAS2R14GAASIGMAR1PNMTTSHR
SCHEMBL5542131 0.76 TAS2R14 (0.45) TAS2R14SIGMAR1PNMTNR3C1PYCR1
SCHEMBL5542357 0.76 TAS2R14 (0.48) TAS2R14GAASIGMAR1PNMTNR3C1
SCHEMBL28028840 0.76 ALDH1A1 (0.42) TSHRG6PC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TAS2R14 1579/4885GAA 4165/4885SIGMAR1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.